{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T17:40:05Z","timestamp":1744566005182,"version":"3.40.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,13]]},"DOI":"10.7759\/cureus.82180","type":"journal-article","created":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T17:23:46Z","timestamp":1744565026000},"source":"Crossref","is-referenced-by-count":0,"title":["Naloxone Prescribing Among Long-Term Opioid-Prescribed Patients: Disparities and Opportunities"],"prefix":"10.7759","author":[{"given":"Brian","family":"Yorkgitis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Harmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fern","family":"Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Brat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6831e1","article-title":"Vital signs: pharmacy-based naloxone dispensing - United States, 2012-2018","volume":"68","author":"Guy GP Jr","year":"2019","unstructured":"Guy GP Jr, Haegerich TM, Evans ME, Losby JL, Young R, Jones CM. Vital signs: pharmacy-based naloxone dispensing - United States, 2012-2018. MMWR Morb Mortal Wkly Rep. 2019, 68:679-86. 10.15585\/mmwr.mm6831e1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref2","unstructured":"Lifesaving naloxone. (2024). Accessed. June 17, 2024: https:\/\/www.cdc.gov\/stop-overdose\/caring\/naloxone.html."},{"key":"ref3","unstructured":"Naloxone DrugFacts. (2024). Accessed. August 28, 2024: https:\/\/nida.nih.gov\/publications\/drugfacts\/naloxone."},{"key":"ref4","unstructured":"FDA approves first over-the-counter naloxone nasal spray. (2024). Accessed. June 17, 2024: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-over-counter-naloxone-nasal-spray."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC guideline for prescribing opioids for chronic pain - United States, 2016","volume":"65","author":"Dowell D","year":"2016","unstructured":"Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. MMWR Recomm Rep. 2016, 65:1-49. 10.15585\/mmwr.rr6501e1","journal-title":"MMWR Recomm Rep"},{"key":"ref6","unstructured":"Rx awareness. (2024). Accessed. July 1, 2024: https:\/\/www.cdc.gov\/rx-awareness\/."},{"key":"ref7","unstructured":"Overdose prevention. (2024). Accessed. July 1, 2024: https:\/\/www.cdc.gov\/overdose-prevention\/."},{"key":"ref8","unstructured":"Life-saving naloxone from pharmacies. (2024). Accessed. August 30, 2024: https:\/\/www.cdc.gov\/vitalsigns\/naloxone\/index.html."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2020.305620","article-title":"Laws mandating coprescription of naloxone and their impact on naloxone prescription in five US states, 2014-2018","volume":"110","author":"Green TC","year":"2020","unstructured":"Green TC, Davis C, Xuan Z, Walley AY, Bratberg J. Laws mandating coprescription of naloxone and their impact on naloxone prescription in five US states, 2014-2018. Am J Public Health. 2020, 110:881-7. 10.2105\/AJPH.2020.305620","journal-title":"Am J Public Health"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2019.1686721","article-title":"Racial inequities in U.S. naloxone prescriptions","volume":"41","author":"Madden EF","year":"2020","unstructured":"Madden EF, Qeadan F. Racial inequities in U.S. naloxone prescriptions. Subst Abus. 2020, 41:232-44. 10.1080\/08897077.2019.1686721","journal-title":"Subst Abus"},{"key":"ref11","unstructured":"Identifying gaps in Veterans Health Administration (VHA) distribution of lifesaving naloxone. (2024). Accessed. June 17, 2024: https:\/\/www.hsrd.research.va.gov\/publications\/forum\/spring24\/default.cfm?ForumMenu=spring24-4."},{"key":"ref12","unstructured":"OCHIN and OCHIN data. (2024). Accessed. August 28, 2024: https:\/\/www.aim-ahead.net\/data-and-research-core\/about-ochin-ochin-data\/."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2019.05.006","article-title":"Development and assessment of a crosswalk between ICD-9-CM and ICD-10-CM to identify patients with common pain conditions","volume":"20","author":"Mayhew M","year":"2019","unstructured":"Mayhew M, DeBar LL, Deyo RA, Kerns RD, Goulet JL, Brandt CA, Von Korff M. Development and assessment of a crosswalk between ICD-9-CM and ICD-10-CM to identify patients with common pain conditions. J Pain. 2019, 20:1429-45. 10.1016\/j.jpain.2019.05.006","journal-title":"J Pain"},{"key":"ref14","unstructured":"New York State (NYS) - issued formulation morphine milligram equivalent (MME) conversion table guidance. (2024). Accessed. August 20, 2024: https:\/\/apps.health.ny.gov\/pub\/ctrldocs\/bne\/nyosammeformulation.pdf."},{"key":"ref15","unstructured":"Drug overdose deaths. facts and figures. (2024). Accessed: August 30, 2024: https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06577-5","article-title":"Individual and community factors associated with naloxone co-prescribing among long-term opioid patients: a retrospective analysis","volume":"36","author":"Stein BD","year":"2021","unstructured":"Stein BD, Smart R, Jones CM, Sheng F, Powell D, Sorbero M. Individual and community factors associated with naloxone co-prescribing among long-term opioid patients: a retrospective analysis. J Gen Intern Med. 2021, 36:2952-7. 10.1007\/s11606-020-06577-5","journal-title":"J Gen Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-019-05423-7","article-title":"Association of opioid overdose risk factors and naloxone prescribing in US adults","volume":"35","author":"Lin LA","year":"2020","unstructured":"Lin LA, Brummett CM, Waljee JF, Englesbe MJ, Gunaseelan V, Bohnert AS. Association of opioid overdose risk factors and naloxone prescribing in US adults. J Gen Intern Med. 2020, 35:420-7. 10.1007\/s11606-019-05423-7","journal-title":"J Gen Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.2663","article-title":"Trends in out-of-pocket costs for naloxone by drug brand and payer in the US, 2010-2018","volume":"3","author":"Peet ED","year":"2022","unstructured":"Peet ED, Powell D, Pacula RL. Trends in out-of-pocket costs for naloxone by drug brand and payer in the US, 2010-2018. JAMA Health Forum. 2022, 3:e222663. 10.1001\/jamahealthforum.2022.2663","journal-title":"JAMA Health Forum"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.8378","article-title":"Association between cost sharing and naloxone prescription dispensing","volume":"332","author":"Chua KP","year":"2024","unstructured":"Chua KP, Conti RM, Lagisetty P, Bohnert AS, He S, Nguyen TD. Association between cost sharing and naloxone prescription dispensing. JAMA. 2024, 332:124-32. 10.1001\/jama.2024.8378","journal-title":"JAMA"},{"key":"ref20","unstructured":"Naloxone prescription mandates. (2024). Accessed. August 28, 2024: https:\/\/www.networkforphl.org\/wp-content\/uploads\/2023\/07\/Fact-Sheet-Naloxone-Prescription-Mandates-2022-update.pdf."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-022-07876-9","article-title":"Electronic advisories increase naloxone prescribing across health care settings","volume":"38","author":"Heiman E","year":"2023","unstructured":"Heiman E, Lanh S, Moran TP, Steck A, Carpenter J. Electronic advisories increase naloxone prescribing across health care settings. J Gen Intern Med. 2023, 38:1402-9. 10.1007\/s11606-022-07876-9","journal-title":"J Gen Intern Med"},{"key":"ref22","unstructured":"When to offer naloxone to patients. (2024). Accessed. August 30, 2024: https:\/\/www.cdc.gov\/overdose-prevention\/media\/pdfs\/2024\/07\/FactSheet-When-to-Offer-Naloxone-to-Patients.pdf."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/341406-naloxone-prescribing-among-long-term-opioid-prescribed-patients-disparities-and-opportunities","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T17:23:49Z","timestamp":1744565029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/341406-naloxone-prescribing-among-long-term-opioid-prescribed-patients-disparities-and-opportunities"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,13]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.82180","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,13]]}}}